Archon Bio is a biotechnology company developing geometrically tunable protein therapeutics that target pathways other technologies cannot. The company is recognized for its innovation in computationally designed biologics.

Archon Bio

Archon Biosciences | 1,193 followers on LinkedIn. Pioneering next-generation antibody therapies with AI and computational protein design  | Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease.  

We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Senior Associate Scientist at Archon Bio

Justin Hare

Sr. Scientist, Immunology

Christie Mortales

Head of Research

Jonathan Graves

Senior Scientist - Biology Lead

Justin Huard

Archon Biosciences

Although we emerged from stealth yesterday, our technology and vision has been developed for over a decade. Beyond innovative science, great biotechs are built on great relationships. We wouldn’t be here today without Madrona ’s conviction and belief in us since day one. Their leadership in AI-driven biotech and commitment to the transformational potential of Antibody Cages (AbCs) have enabled Archon to become a reality. We’re excited to continue this partnership and apply generative protein design to build best-in-class medicines together!

Today, Archon Biosciences announced $20 million in seed financing led by Madrona and shared our vision for the future of drug development! We’ve built a completely novel class of biologics, Antibody Cages (AbCs) designed to unlock powerful therapeutic targets beyond the reach of existing modalities and to better treat disease. AbCs integrate the unparalleled binding properties of antibodies into a boundless set of AI-generated nanostructures that have never existed in nature. Precise control over AbC structures provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold standard for biologic medicines. Learn more in our press release here: https://lnkd.in/eTJxYNuk To see AbCs in action and learn more about how Archon is applying generative protein design to improve human health, visit our website at https://www.archon.bio/ #biotech #antibodies #AI #ComputationalProteinDesign #AbC

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 9, 2024 4:27 AM	d3f6efb6
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 9, 2024 4:27 AM	24a1ed84
crunchbase trigger	general	Nov 9, 2024 4:27 AM	32f7d2dc
crunchbase profile	general
li profile	general	Nov 9, 2024 4:27 AM	49d3952e
translate crunchbase fundingrounds	general
peers	general	Nov 9, 2024 4:27 AM	e0389912
news basic	general	Nov 9, 2024 4:27 AM	e6242801
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ARCH

BIO:ARCHON

Archon Bio